A groundbreaking artificial intelligence tool developed at Cedars-Sinai could revolutionize how physicians select presurgical therapies for breast cancer patients. The tool, known as BRIDGE, was detailed in a recent publication in Annals of Oncology alongside early validation data. Unlike traditional methods that classify a tumor as a single subtype, BRIDGE reads the genetic signals inside a tumor to identify which subtypes are present, offering a more nuanced approach to treatment planning.
Breast cancer is not a single disease but a collection of subtypes, each with distinct genetic profiles and responses to therapy. Standard practice often involves categorizing the entire tumor based on the dominant subtype, which can overlook the presence of other subtypes that may influence treatment efficacy. BRIDGE addresses this limitation by analyzing intratumor heterogeneity, the genetic diversity within a single tumor. By identifying the mix of subtypes, the AI tool can predict which combination of presurgical treatments—such as chemotherapy, targeted therapy, or hormone therapy—would be most effective for each patient.
The implications of this technology are significant. Presurgical, or neoadjuvant, therapy aims to shrink tumors before surgery, improving surgical outcomes and providing early indicators of treatment response. However, selecting the wrong therapy can lead to ineffective treatment and delays in surgery. BRIDGE could help avoid such pitfalls, potentially increasing the rate of pathologic complete response, where no cancer cells remain at the time of surgery, which is associated with better long-term outcomes.
The development of BRIDGE builds on other advances in cancer research from various institutions and companies. For instance, Calidi Biotherapeutics Inc. (NASDAQ: CLDI) is focusing on developing innovative therapies for cancer. However, BRIDGE stands out as a diagnostic tool that leverages AI to optimize existing treatment protocols rather than developing new drugs.
The early validation data published in Annals of Oncology demonstrate BRIDGE's ability to accurately predict treatment responses in retrospective analyses of patient data. Prospective clinical trials are needed to confirm these findings, but the initial results are promising. If validated, BRIDGE could become a standard tool in oncology clinics, guiding personalized treatment decisions and reducing trial-and-error in cancer care.
In summary, BRIDGE represents a significant step forward in precision medicine for breast cancer. By providing a detailed genetic map of a tumor's heterogeneity, it enables more tailored presurgical therapy, potentially improving outcomes for thousands of patients. As AI continues to permeate healthcare, tools like BRIDGE highlight the potential for machine learning to enhance clinical decision-making and personalize treatment at an unprecedented level.
